MP Advisors Market Research Reports

TITLE	Actions
Outlook of Diabetic Macular Edema – Current Landscape and the Way Forward Published in Jul 2020 \| US $ 4500 Onwards \| By MP Advisors Global market for DME was ~$3.7 billion in 2019 with US alone contributing to 51% market share, owing to the higher incidence rates of diabetes amongst the developed nations. In 2018, ~2.4m people in the US had DME, of that only ~70% got diagnosed...
Japan Biosimilars- Landscape Today Outlook Tomorrow “Biosame” entry, uninterrupted supply and companies’ strong front-end footprint requirement makes it distinct - After a decade, JP Biosimilar guidelines’s first revision expected in FY2020 – Demonstrate Chuikyo need of biosimilar tool to curb healthcare cost - Biosimilars uptake varies as per each opportunity, Remicade BS vs. Rituxan BS – Two poles of the curve - A few skipping NHI listing due to manufacturing issues associated with constant supply need, mature CMO in Japan has potential to fulfill this requirement Published in Jan 2020 \| US $ 4500 Onwards \| By MP Advisors Since 2009, 25 biosimilars of 12 originator products are approved in Japan and have yielded mixed performances and attained annual sales of ~¥32.4b ($300m). Unique biosimilars landscape with the entry of NESP “biosame” by originato...
Next Decade Generic String Of Pearls Opportunities: Sustainability Assessment With Respect To Therapeutic Positioning Published in Nov 2017 \| US $ 4000 Onwards \| By MP Advisors The rapid growth of the generic industry has come with a number of challenges, such as heavy competition, including from authorized generics and government-mandated price cuts. All contribute to diminishing prices and ever decreasing margins. In t...
The Future of the U.S. Biologics and Biosimilars Treatment Market for Psoriasis Published in Oct 2017 \| US $ 4000 Onwards \| By MP Advisors The U.S. psoriasis treatment market for Biologics and Biosimilars was estimated at $6.6bn in 2016 is projected to almost double during the forecast period to reach $12.9bn in 2021 driven by safety and efficacy improvements of the new generation bi...
Japan Biosimilars – A start of Authorized Biosimilar Era? Biosimilar/BioPharma CMO opportunities – JP Conglomerates – A definite role to play for Global Market! Major JP Innovator vs. Early entrant Mid size Japanese companies- TA focus approach – A Win Win Game! Published in Aug 2017 \| US $ 4000 Onwards \| By MP Advisors In 2016, encouraging uptake of Lantus BS in Japan confirms strong foothold of the marketer, product mix targeted to DPC hospitals (Diagnostic Procedure Combination hospitals- ~4000) and early entry of the player are critical factors to decide bios...
Prostate Cancer - Newer Antiandrogens & Emerging Therapies Targeting a “Watchful Waiting” and Resistance Population Published in Feb 2017 \| US $ 4500 Onwards \| By MP Advisors Xtandi – Replacing competitor from Zytiga to Casodex (Bicalutamide) for a bigger pie in Prostate cancer & Finding its niche in crowded BC market Xtandi + Zytiga vs. ARN-509 + Zytiga - Who will win the ...
Pain Management- New Discoveries And Treatment Options In Abuse Deterrent Era Published in Sep 2016 \| US $ 3500 Onwards \| By MP Advisors Rescheduling of Hydrocodone combinations from Class III to Class II, clear-cut regulatory guideline for Abuse Deterrent drug formulation NDA & ANDA (solid oral) filing and CDC guideline for Prescribing Opioids for Chr...
India Pharma Outlook 2016: Milestones to Watch – Growth from Exports and Domestic Getting Better, Implementation of Policies under “Make-in-India”, Overture of A New Ministry Published in Mar 2016 \| US $ 1500 Onwards \| By MP Advisors 2016 will be a crucial for drug makers and consumers. During ?Make-in-India' week in Mumbai, Govt. highlighted many amendments or introduction of new policies with an aim to make India as a major hub for end to end drug discovery. To boost drug di...
Large Cap Pharma US & EU Outlook 2016: Maximizing Their Strength On Fewer Therapy Class, Personalized Medicine, Novel Target And Biosimilars For Future Growth Published in Mar 2016 \| US $ 2000 Onwards \| By MP Advisors Major pharma companies are continue to improve the productivity by taking different approaches like focusing on selected therapy area and markets, merger and acquisition, divestment of non-core brands/segments and consolidation in animal health, v...
Japan Pharma Outlook 2016 : JP Giants leaning in for becoming a Speciality Global Pharma Published in Mar 2016 \| US $ 2500 Onwards \| By MP Advisors Sakigake designation - A Push from government to "Innovate"!"Essential drugs" exemption from Z2 rule- Balancing long listed pricing pressure!Authorized Generics, Biosimilars, and Patent Litigations - Avenues to gr...
Rising Stars Outlook 2016 :New Emergence of Potential Tx & Dx Options could transform the Current Landscape for Liver Diseases (NASH) Published in Jan 2016 \| US $ 2000 Onwards \| By MP Advisors Non-Alcoholic SteatoHepatitis (NASH) is an unmet medical need and is becoming the leading cause of liver transplant. No FDA-approved therapies and a meager diagnosis, it poses a unique challenge in the design of studies for NASH. Therefore, there ...
Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in development, Regulatory guidelines and Market opportunity in Various Geographies Published in Dec 2015 \| US $ 3500 Onwards \| By MP Advisors Sales of Hepatitis C drugs crossed ~$10bn in 2014 proving that treatments for liver disease could become mega-blockbusters and Non-Alcoholic SteatoHepatitis (NASH) is expected to be equally lucrative. Improved diagnosis rate and change in tr...
Japan Biosimilar- Active Players In Quest of a Specialty & Niche BS space Published in Dec 2015 \| US $ 4000 Onwards \| By MP Advisors Filgrastim BS and Lantus BS Approval- Encouraging uptake and a lesson to fast track JP approval based on Ex-Japan data!Remicade biosimilar “NK” – A slow start does not pull back NK in starting PhIII for Herceptin BS in Jap...
BUCCAL DRUG DELIVERY SYSTEMS: OPPORTUNITIES AND CHALLENGES IN BUCCAL, SUBLINGUAL FILMS, TABLETS & SPRAYS - Detailed analysis on Technologies and Pipeline Development Published in Oct 2015 \| US $ 3000 Onwards \| By MP Advisors Within the oral mucosal cavity, the buccal region offers an attractive route of administration for systemic drug delivery. The mucosa has a rich blood supply and it is relatively permeable. The buccal mucosa offers several advantages for con...
India Pharma Outlook 2015: Accelerating growth to the next level: Moving up the value chain beyond Generics Published in Feb 2015 \| US $ 2000 Onwards \| By MP Advisors Domestic sales improved in 2014, recovering from the slump in the 2013 caused by the market's reaction to the new drug pricing policy. In 2015, growth is expected to continue to be healthy, as the momentum continues and improving economic grow...
Japan Pharma Outlook 2015: 2015 –Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives Published in Jan 2015 \| US $ 2000 Onwards \| By MP Advisors The new pricing system adopted in Japan from April -2014 (Annexure 1) is a game changer initiative. It pains most of the companies - whether generic or innovator. The most of the companies are revalidating their domestic (and thus overseas) strate...
Sri Lanka Pharma Market Outlook 2015: More beyond Importers & Distributors Published in Jan 2015 \| US $ 2000 Onwards \| By MP Advisors With the recent development, Sri Lanka's aim of developing a pharma industry should be to penetrate the global market since the internal market is not sufficient for any big firm to operate at optimum levels. According to a report published by...
Global Pharma US & EU Outlook 2015 : First –In- Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies Published in Jan 2015 \| US $ 2000 Onwards \| By MP Advisors Strategy Diversification Divested: Productivity measurements, Divestment of non-core assets resulting in healthy Cash position- Will accelerate Next wave of targeted acquisition. In the recent years several new therapies have been approved...
Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success Published in Jan 2015 \| US $ 2000 Onwards \| By MP Advisors All biotech companies - Gilead (GILD), Amgen (AMGN), Biogen Idec (BIIB) and Celgene (CELG), in past year, have given a positive return and hence increased the interest of biotech investors. These companies have been able to select therapy/niche in...
Hematological Malignancies: Multiple Myeloma (MM) – Early and Robust Diagnosis along with New Treatment Options can have Considerable Impact on Management of the Disease Published in Jan 2015 \| US $ 3000 Onwards \| By MP Advisors While targeting unmet needs in the treatment of hematological malignancies/ cancer through innovative drug development strategies have witnessed favorable outcomes, the specific choice of the therapies is dependent on the identification of importa...

We are on:

Need Help?

Name *

Email *

Phone *

Country *

Subject *

Comments *

TITLE	Actions
Outlook of Diabetic Macular Edema – Current Landscape and the Way Forward Published in Jul 2020 \| US $ 4500 Onwards \| By MP Advisors Global market for DME was ~$3.7 billion in 2019 with US alone contributing to 51% market share, owing to the higher incidence rates of diabetes amongst the developed nations. In 2018, ~2.4m people in the US had DME, of that only ~70% got diagnosed...
Japan Biosimilars- Landscape Today Outlook Tomorrow “Biosame” entry, uninterrupted supply and companies’ strong front-end footprint requirement makes it distinct - After a decade, JP Biosimilar guidelines’s first revision expected in FY2020 – Demonstrate Chuikyo need of biosimilar tool to curb healthcare cost - Biosimilars uptake varies as per each opportunity, Remicade BS vs. Rituxan BS – Two poles of the curve - A few skipping NHI listing due to manufacturing issues associated with constant supply need, mature CMO in Japan has potential to fulfill this requirement Published in Jan 2020 \| US $ 4500 Onwards \| By MP Advisors Since 2009, 25 biosimilars of 12 originator products are approved in Japan and have yielded mixed performances and attained annual sales of ~¥32.4b ($300m). Unique biosimilars landscape with the entry of NESP “biosame” by originato...
Next Decade Generic String Of Pearls Opportunities: Sustainability Assessment With Respect To Therapeutic Positioning Published in Nov 2017 \| US $ 4000 Onwards \| By MP Advisors The rapid growth of the generic industry has come with a number of challenges, such as heavy competition, including from authorized generics and government-mandated price cuts. All contribute to diminishing prices and ever decreasing margins. In t...
The Future of the U.S. Biologics and Biosimilars Treatment Market for Psoriasis Published in Oct 2017 \| US $ 4000 Onwards \| By MP Advisors The U.S. psoriasis treatment market for Biologics and Biosimilars was estimated at $6.6bn in 2016 is projected to almost double during the forecast period to reach $12.9bn in 2021 driven by safety and efficacy improvements of the new generation bi...
Japan Biosimilars – A start of Authorized Biosimilar Era? Biosimilar/BioPharma CMO opportunities – JP Conglomerates – A definite role to play for Global Market! Major JP Innovator vs. Early entrant Mid size Japanese companies- TA focus approach – A Win Win Game! Published in Aug 2017 \| US $ 4000 Onwards \| By MP Advisors In 2016, encouraging uptake of Lantus BS in Japan confirms strong foothold of the marketer, product mix targeted to DPC hospitals (Diagnostic Procedure Combination hospitals- ~4000) and early entry of the player are critical factors to decide bios...
Prostate Cancer - Newer Antiandrogens & Emerging Therapies Targeting a “Watchful Waiting” and Resistance Population Published in Feb 2017 \| US $ 4500 Onwards \| By MP Advisors Xtandi – Replacing competitor from Zytiga to Casodex (Bicalutamide) for a bigger pie in Prostate cancer & Finding its niche in crowded BC market Xtandi + Zytiga vs. ARN-509 + Zytiga - Who will win the ...
Pain Management- New Discoveries And Treatment Options In Abuse Deterrent Era Published in Sep 2016 \| US $ 3500 Onwards \| By MP Advisors Rescheduling of Hydrocodone combinations from Class III to Class II, clear-cut regulatory guideline for Abuse Deterrent drug formulation NDA & ANDA (solid oral) filing and CDC guideline for Prescribing Opioids for Chr...
India Pharma Outlook 2016: Milestones to Watch – Growth from Exports and Domestic Getting Better, Implementation of Policies under “Make-in-India”, Overture of A New Ministry Published in Mar 2016 \| US $ 1500 Onwards \| By MP Advisors 2016 will be a crucial for drug makers and consumers. During ?Make-in-India' week in Mumbai, Govt. highlighted many amendments or introduction of new policies with an aim to make India as a major hub for end to end drug discovery. To boost drug di...
Large Cap Pharma US & EU Outlook 2016: Maximizing Their Strength On Fewer Therapy Class, Personalized Medicine, Novel Target And Biosimilars For Future Growth Published in Mar 2016 \| US $ 2000 Onwards \| By MP Advisors Major pharma companies are continue to improve the productivity by taking different approaches like focusing on selected therapy area and markets, merger and acquisition, divestment of non-core brands/segments and consolidation in animal health, v...
Japan Pharma Outlook 2016 : JP Giants leaning in for becoming a Speciality Global Pharma Published in Mar 2016 \| US $ 2500 Onwards \| By MP Advisors Sakigake designation - A Push from government to "Innovate"!"Essential drugs" exemption from Z2 rule- Balancing long listed pricing pressure!Authorized Generics, Biosimilars, and Patent Litigations - Avenues to gr...
Rising Stars Outlook 2016 :New Emergence of Potential Tx & Dx Options could transform the Current Landscape for Liver Diseases (NASH) Published in Jan 2016 \| US $ 2000 Onwards \| By MP Advisors Non-Alcoholic SteatoHepatitis (NASH) is an unmet medical need and is becoming the leading cause of liver transplant. No FDA-approved therapies and a meager diagnosis, it poses a unique challenge in the design of studies for NASH. Therefore, there ...
Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in development, Regulatory guidelines and Market opportunity in Various Geographies Published in Dec 2015 \| US $ 3500 Onwards \| By MP Advisors Sales of Hepatitis C drugs crossed ~$10bn in 2014 proving that treatments for liver disease could become mega-blockbusters and Non-Alcoholic SteatoHepatitis (NASH) is expected to be equally lucrative. Improved diagnosis rate and change in tr...
Japan Biosimilar- Active Players In Quest of a Specialty & Niche BS space Published in Dec 2015 \| US $ 4000 Onwards \| By MP Advisors Filgrastim BS and Lantus BS Approval- Encouraging uptake and a lesson to fast track JP approval based on Ex-Japan data!Remicade biosimilar “NK” – A slow start does not pull back NK in starting PhIII for Herceptin BS in Jap...
BUCCAL DRUG DELIVERY SYSTEMS: OPPORTUNITIES AND CHALLENGES IN BUCCAL, SUBLINGUAL FILMS, TABLETS & SPRAYS - Detailed analysis on Technologies and Pipeline Development Published in Oct 2015 \| US $ 3000 Onwards \| By MP Advisors Within the oral mucosal cavity, the buccal region offers an attractive route of administration for systemic drug delivery. The mucosa has a rich blood supply and it is relatively permeable. The buccal mucosa offers several advantages for con...
India Pharma Outlook 2015: Accelerating growth to the next level: Moving up the value chain beyond Generics Published in Feb 2015 \| US $ 2000 Onwards \| By MP Advisors Domestic sales improved in 2014, recovering from the slump in the 2013 caused by the market's reaction to the new drug pricing policy. In 2015, growth is expected to continue to be healthy, as the momentum continues and improving economic grow...
Japan Pharma Outlook 2015: 2015 –Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives Published in Jan 2015 \| US $ 2000 Onwards \| By MP Advisors The new pricing system adopted in Japan from April -2014 (Annexure 1) is a game changer initiative. It pains most of the companies - whether generic or innovator. The most of the companies are revalidating their domestic (and thus overseas) strate...
Sri Lanka Pharma Market Outlook 2015: More beyond Importers & Distributors Published in Jan 2015 \| US $ 2000 Onwards \| By MP Advisors With the recent development, Sri Lanka's aim of developing a pharma industry should be to penetrate the global market since the internal market is not sufficient for any big firm to operate at optimum levels. According to a report published by...
Global Pharma US & EU Outlook 2015 : First –In- Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies Published in Jan 2015 \| US $ 2000 Onwards \| By MP Advisors Strategy Diversification Divested: Productivity measurements, Divestment of non-core assets resulting in healthy Cash position- Will accelerate Next wave of targeted acquisition. In the recent years several new therapies have been approved...
Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success Published in Jan 2015 \| US $ 2000 Onwards \| By MP Advisors All biotech companies - Gilead (GILD), Amgen (AMGN), Biogen Idec (BIIB) and Celgene (CELG), in past year, have given a positive return and hence increased the interest of biotech investors. These companies have been able to select therapy/niche in...
Hematological Malignancies: Multiple Myeloma (MM) – Early and Robust Diagnosis along with New Treatment Options can have Considerable Impact on Management of the Disease Published in Jan 2015 \| US $ 3000 Onwards \| By MP Advisors While targeting unmet needs in the treatment of hematological malignancies/ cancer through innovative drug development strategies have witnessed favorable outcomes, the specific choice of the therapies is dependent on the identification of importa...